350 related articles for article (PubMed ID: 23487027)
1. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
[TBL] [Abstract][Full Text] [Related]
2. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
Lu M; Xia L; Li Y; Wang X; Hoffman R
Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
[TBL] [Abstract][Full Text] [Related]
3. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
[TBL] [Abstract][Full Text] [Related]
5. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
6. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
Lu M; Wang J; Li Y; Berenzon D; Wang X; Mascarenhas J; Xu M; Hoffman R
Blood; 2010 Nov; 116(20):4284-7. PubMed ID: 20625010
[TBL] [Abstract][Full Text] [Related]
7. Critical requirement for Stat5 in a mouse model of polycythemia vera.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
[TBL] [Abstract][Full Text] [Related]
8. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
9. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
King KY; Matatall KA; Shen CC; Goodell MA; Swierczek SI; Prchal JT
Exp Hematol; 2015 Oct; 43(10):912-918.e2. PubMed ID: 26072330
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
Mullally A; Poveromo L; Schneider RK; Al-Shahrour F; Lane SW; Ebert BL
Blood; 2012 Jul; 120(1):166-72. PubMed ID: 22627765
[TBL] [Abstract][Full Text] [Related]
11. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Dagher T; Maslah N; Edmond V; Cassinat B; Vainchenker W; Giraudier S; Pasquier F; Verger E; Niwa-Kawakita M; Lallemand-Breitenbach V; Plo I; Kiladjian JJ; Villeval JL; de Thé H
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33075130
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
[TBL] [Abstract][Full Text] [Related]
13. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
Shepherd MS; Li J; Wilson NK; Oedekoven CA; Li J; Belmonte M; Fink J; Prick JCM; Pask DC; Hamilton TL; Loeffler D; Rao A; Schröder T; Göttgens B; Green AR; Kent DG
Blood; 2018 Aug; 132(8):791-803. PubMed ID: 29991556
[TBL] [Abstract][Full Text] [Related]
14. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.
Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H
Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of vorinostat in a murine model of polycythemia vera.
Akada H; Akada S; Gajra A; Bair A; Graziano S; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(16):3779-89. PubMed ID: 22408262
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
[TBL] [Abstract][Full Text] [Related]
17. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
[TBL] [Abstract][Full Text] [Related]
18. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 mutation.
Merchant S
Int Rev Cell Mol Biol; 2021; 365():117-162. PubMed ID: 34756242
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
Wernig G; Kharas MG; Okabe R; Moore SA; Leeman DS; Cullen DE; Gozo M; McDowell EP; Levine RL; Doukas J; Mak CC; Noronha G; Martin M; Ko YD; Lee BH; Soll RM; Tefferi A; Hood JD; Gilliland DG
Cancer Cell; 2008 Apr; 13(4):311-20. PubMed ID: 18394554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
